Published in Bioorg Med Chem on July 08, 2008
Synthesis and molecular modeling of novel tetrahydro-β-carboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties. J Med Chem (2010) 0.89
Design, synthesis, and biological evaluation of callophycin A and analogues as potential chemopreventive and anticancer agents. Bioorg Med Chem (2011) 0.82
Fascaplysin as a specific inhibitor for CDK4: insights from molecular modelling. PLoS One (2012) 0.82
Synthesis of rigidified eIF4E/eIF4G inhibitor-1 (4EGI-1) mimetic and their in vitro characterization as inhibitors of protein-protein interaction. J Med Chem (2014) 0.76
The diketopiperazine-fused tetrahydro-β-carboline scaffold as a model peptidomimetic with an unusual α-turn secondary structure. Beilstein J Org Chem (2013) 0.75
Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature (2007) 19.33
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol (2006) 8.58
What is a surgical complication? World J Surg (2008) 7.85
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04
NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw (2010) 5.98
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst (2009) 4.87
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
Shaping cities for health: complexity and the planning of urban environments in the 21st century. Lancet (2012) 4.51
New paradigms for supporting the resilience of marine ecosystems. Trends Ecol Evol (2005) 4.11
Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis (2008) 3.98
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92
Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med (2010) 3.90
Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol (2003) 3.73
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol (2007) 3.65
Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol (2014) 3.17
Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov (2012) 2.76
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol (2008) 2.68
Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol (2006) 2.46
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res (2011) 2.23
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol (2008) 2.20
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin (2010) 2.05
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol (2004) 2.02
Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol (2008) 1.98
NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw (2009) 1.97
Management of complications of prostate cancer treatment. CA Cancer J Clin (2008) 1.91
Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol (2009) 1.86
Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res (2010) 1.82
Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer (2005) 1.72
Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer (2004) 1.69
Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol (2010) 1.66
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2006) 1.65
Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol (2012) 1.65
Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol (2012) 1.64
Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer (2004) 1.64
Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clin Cancer Res (2004) 1.63
Treatment and prevention of bone complications from prostate cancer. Bone (2010) 1.60
Use of androgen deprivation therapy for metastatic prostate cancer in older men. BJU Int (2008) 1.59
Interlaboratory comparison of PCR-based identification and genogrouping of Neisseria meningitidis. J Clin Microbiol (2005) 1.56
Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine (2012) 1.54
Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab (2014) 1.53
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol (2013) 1.51
Clinical decisions. Screening for prostate cancer. N Engl J Med (2012) 1.49
Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention? BJU Int (2010) 1.40
The right to public health. J Med Ethics (2016) 1.39
Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol (2010) 1.36
Localising loci underlying complex trait variation using Regional Genomic Relationship Mapping. PLoS One (2012) 1.34
A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res (2013) 1.33
Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev (2008) 1.32
Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev (2010) 1.32
Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J Clin Microbiol (2009) 1.32
Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol (2011) 1.31
Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31. Cancer (2007) 1.28
Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer. J Urol (2011) 1.27
Invasive meningococcal capsular group Y disease, England and Wales, 2007-2009. Emerg Infect Dis (2012) 1.26
Three cases of invasive meningococcal disease caused by a capsule null locus strain circulating among healthy carriers in Burkina Faso. J Infect Dis (2007) 1.23
Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther (2002) 1.22
Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psychooncology (2002) 1.22
Association of a bacteriophage with meningococcal disease in young adults. PLoS One (2008) 1.22
Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int (2002) 1.21
Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol (2013) 1.21
Adaptive management of the Great Barrier Reef and the Grand Canyon world heritage areas. Ambio (2007) 1.21
Measurement of oxidative DNA damage induced by mainstream cigarette smoke in cultured NCI-H292 human pulmonary carcinoma cells. Mutat Res (2008) 1.20
Changes in serogroup and genotype prevalence among carried meningococci in the United Kingdom during vaccine implementation. J Infect Dis (2011) 1.19
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist (2007) 1.16
Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. Nephrol Dial Transplant (2003) 1.14
Magnetoencephalographic recordings of visual evoked brain activity in the human fetus. Lancet (2002) 1.12
Interlaboratory comparison of agar dilution and Etest methods for determining the MICs of antibiotics used in management of Neisseria meningitidis infections. Antimicrob Agents Chemother (2003) 1.10
Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol (2005) 1.10
Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer (2009) 1.09
Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer. Cancer J (2013) 1.09
Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes (2010) 1.09
Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer (2007) 1.09
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol (2008) 1.08
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst (2012) 1.07
A structured exercise program for patients with advanced non-small cell lung cancer. J Thorac Oncol (2009) 1.06
Commute times, food retail gaps, and body mass index in North Carolina counties. Prev Chronic Dis (2010) 1.05
The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int (2010) 1.04
Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med (2009) 1.03
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Canc Netw (2009) 1.03
Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. Clin Lymphoma Myeloma (2007) 1.02
Molecular epidemiology of meningococcal disease in England and Wales 1975-1995, before the introduction of serogroup C conjugate vaccines. Microbiology (2008) 1.01
Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence. Sci Transl Med (2013) 1.00
Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res (2008) 1.00
Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy. Cancer (2012) 0.99
Influence of the combination and phase variation status of the haemoglobin receptors HmbR and HpuAB on meningococcal virulence. Microbiology (2011) 0.99
Synthesis, crystal structure and biological activity of beta-carboline based selective CDK4-cyclin D1 inhibitors. Org Biomol Chem (2006) 0.97
Prolonged biologically active colonic tissue levels of curcumin achieved after oral administration--a clinical pilot study including assessment of patient acceptability. Cancer Prev Res (Phila) (2012) 0.96
New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol (2012) 0.95
Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opin Investig Drugs (2006) 0.95
Fatal outcome from meningococcal disease--an association with meningococcal phenotype but not with reduced susceptibility to benzylpenicillin. J Med Microbiol (2002) 0.94
Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics. J Med Chem (2002) 0.93
Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant (2004) 0.93
Multilocus sequence typing of Neisseria meningitidis directly from clinical samples and application of the method to the investigation of meningococcal disease case clusters. J Clin Microbiol (2005) 0.92
Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psychooncology (2008) 0.92
Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. Oncologist (2012) 0.92